General
Preferred name
MRE-269
Synonyms
MRE 269 ()
ACT-333679 ()
MRE269 ()
MRE-269 (ACT-333679) ()
LASELIPAG ()
J2.120.976G ()
ACT333679 ()
MRE-269-d6 ()
P&D ID
PD020197
CAS
475085-57-5
1265295-56-4
Tags
available
drug candidate
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION MRE-269 is the active metabolite of the approved drug .
DESCRIPTION MRE-269 is the active metabolite of the approved drug . MRE-269 behaves as a partial agonist in cAMP assays . (GtoPdb)
DESCRIPTION MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist.
PRICE 75
DESCRIPTION MRE-269 (ACT-333679) is an orally available and long-acting prostacyclin receptor agonist prodrug. MRE-269(ACT-333679) is used for the treatment of pulmonary arterial hypertension. MRE-269(ACT-333679) is an active metabolite of Selexipag (S253150). (TargetMol Bioactive Compound Library)
Compound Sets
12
Cayman Chemical Bioactives
10010412
43917
ChEMBL Drugs
CHEMBL239226
Concise Guide to Pharmacology 2019/20
5852
Concise Guide to Pharmacology 2021/22
5852
Concise Guide to Pharmacology 2023/24
5852
EU-OPENSCREEN Bioactive Compound Library
EOS101529
EUbOPEN Chemogenomics Library
EUB0001845
Guide to Pharmacology
5852
MedChem Express Bioactive Compound Library
HY-79593
Novartis Chemogenetic Library (NIBR MoA Box)
Selleckchem Bioactive Compound Library
mre-269-act-333679
TargetMol Bioactive Compound Library
T3S2007
External IDs
25
Properties
(calculated by RDKit )
Molecular Weight
419.22
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
11
Ring Count
3
Aromatic Ring Count
3
cLogP
4.91
TPSA
75.55
Fraction CSP3
0.32
Chiral centers
0.0
Largest ring
6.0
QED
0.45
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
prostaglandin I2 receptor
Prostaglandin Receptor
Member status
member
MOA
PTGIR agonist
Prostacyclin agonist
Pathway
GPCR/G protein
Immunology/Inflammation
Recommended Cell Concentration
None
Source data